Mechanism of Action Video of Lenabasum

View Video

Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases

Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities

Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases

Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities

Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases

Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities
About

About

Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

Learn More
Technology

Technology

Our technology revolves around the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases.

Learn More
Indications

Indications

Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with rare chronic inflammatory conditions.

Learn More

Pipeline

Corbus Pharmaceuticals is developing lenabasum for the treatment of rare, chronic and serious inflammatory and fibrotic diseases.

View Details
Preclinical Phase 1 Phase 2 Phase 2b Phase 3
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase complete
Phase 3 Phase in progress
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase in progress
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started

Lenabasum

A novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

Sign up for
Email Alerts

Receive breaking news first!

Sign up today

Investor
Presentation

Fact
Sheet

Fact Sheet
(Japanese Translation)